Therapy of systemic sclerosis

The treatment of the patient with Systemic Sclerosis has greatly improved in the last ten years, because of two kinds of achievements. A number of drugs have been demonstrated to be active in some disease manifestations like alveolitis, pulmonary hypertension and complicated Raynaud’s phenomenon. So...

Full description

Bibliographic Details
Main Author: G. Valentini
Format: Article
Language:English
Published: PAGEPress Publications 2004-03-01
Series:Reumatismo
Online Access:https://reumatismo.org/index.php/reuma/article/view/142
_version_ 1818040926107336704
author G. Valentini
author_facet G. Valentini
author_sort G. Valentini
collection DOAJ
description The treatment of the patient with Systemic Sclerosis has greatly improved in the last ten years, because of two kinds of achievements. A number of drugs have been demonstrated to be active in some disease manifestations like alveolitis, pulmonary hypertension and complicated Raynaud’s phenomenon. Some of these drugs namely cyclophosphamide and iloprost await to be confirmed as disease modifying agents. The methological approach to be made in clinical trials has been defined allowing to correctly analyze the results of published trials and plan future ones.
first_indexed 2024-12-10T08:22:17Z
format Article
id doaj.art-5c9e1624de464d97b8b73813eef2220e
institution Directory Open Access Journal
issn 0048-7449
2240-2683
language English
last_indexed 2024-12-10T08:22:17Z
publishDate 2004-03-01
publisher PAGEPress Publications
record_format Article
series Reumatismo
spelling doaj.art-5c9e1624de464d97b8b73813eef2220e2022-12-22T01:56:19ZengPAGEPress PublicationsReumatismo0048-74492240-26832004-03-0156110.4081/reumatismo.2004.1Therapy of systemic sclerosisG. ValentiniThe treatment of the patient with Systemic Sclerosis has greatly improved in the last ten years, because of two kinds of achievements. A number of drugs have been demonstrated to be active in some disease manifestations like alveolitis, pulmonary hypertension and complicated Raynaud’s phenomenon. Some of these drugs namely cyclophosphamide and iloprost await to be confirmed as disease modifying agents. The methological approach to be made in clinical trials has been defined allowing to correctly analyze the results of published trials and plan future ones.https://reumatismo.org/index.php/reuma/article/view/142
spellingShingle G. Valentini
Therapy of systemic sclerosis
Reumatismo
title Therapy of systemic sclerosis
title_full Therapy of systemic sclerosis
title_fullStr Therapy of systemic sclerosis
title_full_unstemmed Therapy of systemic sclerosis
title_short Therapy of systemic sclerosis
title_sort therapy of systemic sclerosis
url https://reumatismo.org/index.php/reuma/article/view/142
work_keys_str_mv AT gvalentini therapyofsystemicsclerosis